- Report
- August 2025
- 124 Pages
Global
From €2267EUR$2,549USD£1,994GBP
€2667EUR$2,999USD£2,346GBP
- Report
- October 2025
- 196 Pages
Global
From €3153EUR$3,545USD£2,774GBP
€3503EUR$3,939USD£3,082GBP
- Report
- January 2025
- 175 Pages
Global
From €3993EUR$4,490USD£3,513GBP
- Report
- April 2025
- 200 Pages
Global
From €2214EUR$2,490USD£1,948GBP
- Report
- April 2025
- 200 Pages
Global
From €3993EUR$4,490USD£3,513GBP
- Report
- March 2025
- 200 Pages
Global
From €3993EUR$4,490USD£3,513GBP
- Report
- September 2023
- 180 Pages
Global
From €5292EUR$5,950USD£4,655GBP
- Report
- June 2024
- 200 Pages
Global
From €5656EUR$6,360USD£4,976GBP
€7070EUR$7,950USD£6,220GBP
- Report
- June 2022
- 320 Pages
Global
From €9890EUR$11,120USD£8,700GBP
€12362EUR$13,900USD£10,875GBP
- Report
- January 2024
- 206 Pages
Global
From €3958EUR$4,450USD£3,482GBP
- Report
- June 2023
- 280 Pages
Global
From €2223EUR$2,500USD£1,956GBP

Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more